These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 20730699

  • 1. Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure.
    Tamargo J, Duarte J, Caballero R, Delpón E.
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1039-47. PubMed ID: 20730699
    [Abstract] [Full Text] [Related]

  • 2. Soluble guanylate cyclase activation with cinaciguat: a new approach to the treatment of decompensated heart failure.
    Hingorany S, Frishman WH.
    Cardiol Rev; 2011 Sep; 19(1):23-9. PubMed ID: 21135599
    [Abstract] [Full Text] [Related]

  • 3. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
    Boerrigter G, Burnett JC.
    Cardiovasc Drug Rev; 2007 Sep; 25(1):30-45. PubMed ID: 17445086
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure.
    Lapp H, Mitrovic V, Franz N, Heuer H, Buerke M, Wolfertz J, Mueck W, Unger S, Wensing G, Frey R.
    Circulation; 2009 Jun 02; 119(21):2781-8. PubMed ID: 19451356
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.
    Chester M, Seedorf G, Tourneux P, Gien J, Tseng N, Grover T, Wright J, Stasch JP, Abman SH.
    Am J Physiol Lung Cell Mol Physiol; 2011 Nov 02; 301(5):L755-64. PubMed ID: 21856817
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus.
    Chester M, Tourneux P, Seedorf G, Grover TR, Gien J, Abman SH.
    Am J Physiol Lung Cell Mol Physiol; 2009 Aug 02; 297(2):L318-25. PubMed ID: 19465519
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers.
    Frey R, Mück W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G.
    J Clin Pharmacol; 2008 Dec 02; 48(12):1400-10. PubMed ID: 18779378
    [Abstract] [Full Text] [Related]

  • 13. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.
    Erdmann E, Semigran MJ, Nieminen MS, Gheorghiade M, Agrawal R, Mitrovic V, Mebazaa A.
    Eur Heart J; 2013 Jan 02; 34(1):57-67. PubMed ID: 22778174
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase.
    Roger S, Paysant J, Badier-Commander C, Cordi A, Verbeuren TJ, Félétou M.
    Vascul Pharmacol; 2010 Jan 02; 53(5-6):281-7. PubMed ID: 20933607
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure.
    Mueck W, Frey R.
    Clin Pharmacokinet; 2010 Jan 02; 49(2):119-29. PubMed ID: 20067336
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.